RECURRENT CANCER

This study tests a personalized vaccine made from each patient's unique tumor mutations. The vaccine is designed to train the immune system to attack the cancer. Ten adults with advanced or high-risk solid tumors will receive the vaccine along with immune-boosting drugs. The goal…

This study tests new cancer drugs that are chosen based on the unique genetic makeup of each child's tumor. It includes up to 90 children, teens, and young adults with advanced solid tumors, brain tumors, or lymphomas that have not responded to standard treatments. The goal is to…

This study tests a new treatment using a patient's own immune cells, modified to recognize and attack cancer cells that carry a specific marker called PRAME. The treatment is given alone or with another drug (nivolumab) to adults with solid tumors that have come back or not respo…

This study tests a drug called cabozantinib in 20 adults whose liver cancer returned after a liver transplant. The goal is to see if the drug can control the cancer. Participants take the drug until it stops working or side effects become too bothersome.

This study is testing a new way to deliver radiation for cervical cancer or pelvic cancer that has come back. It is for patients whose cancer cannot be treated with the usual brachytherapy method because of unusual anatomy or large tumors. The goal is to see if this new technique…

This early-stage trial tests a new drug, IMA402, designed to help the immune system attack cancer cells. It is for adults with solid tumors that have returned or not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors.

This study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…